{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
US Approved Rx
(1993)
Source:
NDA020201
(1993)
Source URL:
First approved in 1978
Source:
DOBUTREX by LILLY
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not
cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Carbazeran is a potent PDE-II and PDE-III inhibitor. Potently inhibits cAMP hydrolysis. Shows chronotropic and inotropic effect in vivo (EC50 = 100 μM, ionotropic effects, independent of adrenergic mechanisms). Carbazeran is a potent cardiac stimulant. Phosphodiesterase inhibition and elevation of intracellular cyclic AMP concentration may be involved, at least in part, in carbazeran`s cardiac effect.
Status:
US Previously Marketed
Source:
IMAGENT by VESSELON SPV LLC
(2002)
Source URL:
First approved in 2002
Source:
IMAGENT by VESSELON SPV LLC
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Perflexane is a contrast agent for ultrasound Imaging. The mechanism of action of perflexane is an ultrasound contrast activity. Perflexane is a fluorinated hydrocarbon and gaseous substance used as an imaging contrast agent in the echocardiogram. After administration in microsphere form, perflexane increases ultrasound reflectivity of blood. This leads to an improvement of ultrasound signaling. Perflexane-lipid microspheres (AFO150) is a preparation of perfluorocarbon (PFC)-based micro bubbles it was approved by the Food and Drug Administration in 2002 for clinical use in echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. However, AFO150 is not currently available for clinical applications.
Status:
Possibly Marketed Outside US
Source:
NCT02200978: Phase 4 Interventional Completed Childhood Acute Promyelocytic Leukemia
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Tanshinone IIA is a derivative of phenanthrene-quinone isolated from Danshen, a widely used Chinese herbal medicine. It has antioxidant properties and cytotoxic activity against multiple human cancer cell lines, inducing apoptosis and differentiation of some human cancer cell lines. It was found, that tanshinone IIA might have potential anticancer activity on breast cancers through upregulation and downregulation of multiple genes involved in cell cycle regulation, cell proliferation, apoptosis, signal transduction, transcriptional regulation, angiogenesis, invasive potential and metastatic potential of cancer cells. ADPRTL1 might be the main target at which tanshinone IIA acted. Recently was discovered that tanshinone IIA exerts its cardio protective effects against H2O2-induced cell death by upregulating the expression of Bcl-2 via the activation of the PI3K/Akt signaling pathway, however, further studies are required in order to define and clarify the rationale for its clinical use.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
MANGANESE GLYCINATE is composed of trace mineral manganese and an amino acid, glycine. It is easily absorbable. It helps the body in a variety of ways including formation of clotting factors, connective tissue sex hormones and bones. It helps in the absorption of calcium and metabolism of carbohydrate as well as fat. It plays an important role for normal nerve and brain function. Moreover, it is a component of the enzyme, superoxide dismutase which helps fighting free radicals. Decreased manganese level can cause infertility, seizures, weakness and bone malformation. Manganese Glycinate (Mn(glycinate)2) has application as a contrast enhancement agent for magnetic resonance imaging in the heart. Toxicity, which is primarily due to the action of manganese as a calcium channel
blocker with effects on muscle electrophysiology and contractility, has limited the use of manganese salts as paramagnetic contrast agents. Mn(glycinate)2 exerts its negative inotropic effect, at least partially, by interfering with the function of the L-type Ca channels at high concentrations.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
BISBUTYTIAMINE is a Vitamin B derivative, analgesic. BISBUTYTIAMINE has being shown to be useful for preventing and treating AIDS, because it has the effect of inhibiting the growth of HIV on early infected cells without killing the cells and both of the cytocidal and HIV-killing effects on the cells that have come to produce HIV continuously.
Status:
US Approved Rx
(1993)
Source:
NDA020201
(1993)
Source URL:
First approved in 1978
Source:
DOBUTREX by LILLY
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not
cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Status:
US Approved Rx
(1993)
Source:
NDA020201
(1993)
Source URL:
First approved in 1978
Source:
DOBUTREX by LILLY
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not
cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Status:
US Approved Rx
(1993)
Source:
NDA020201
(1993)
Source URL:
First approved in 1978
Source:
DOBUTREX by LILLY
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not
cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.
Status:
US Approved Rx
(1993)
Source:
NDA020201
(1993)
Source URL:
First approved in 1978
Source:
DOBUTREX by LILLY
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Conditions:
Dobutamine is a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. Dobutamine hydrochloride is a direct-acting inotropic agent whose primary activity results from stimulation of the ß-receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects. It does not
cause the release of endogenous norepinephrine, as does dopamine. Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures.